Open AccessTHREE-YEAR TREATMENT OUTCOMES OF AFLIBERCEPT VERSUS RANIBIZUMAB FOR DIABETIC MACULAR EDEMA
Author(s) -
PierreHenry Gabrielle,
Vuong Nguyen,
Catherine CreuzotGarcher,
Jennifer Arnold,
Hemal Mehta,
M. Asencio Durán,
Walid Bougamha,
Ester Carreño,
Francesco Viola,
David Squirrell,
Daniel Barthelmes,
Mark Gillies
Publication year - 2022
Publication title -
retina
Language(s) - English
Resource type - Journals
eISSN - 1539-2864
pISSN - 0275-004X
DOI - 10.1097/iae.0000000000003428
Subject(s) - aflibercept , ranibizumab , medicine , visual acuity , diabetic retinopathy , ophthalmology , macular edema , diabetic macular edema , diabetes mellitus , surgery , bevacizumab , chemotherapy , endocrinology
Compare the 3-year outcomes of ranibizumab versus aflibercept in eyes with diabetic macular edema in daily practice.